Molecular Biomarkers Linking Psoriasis and Cardiovascular Disease: Current Evidence and Clinical Perspectives
- 1Department of Dermatology and Venereology, Medical University of Bialystok, 15-540 Bialystok, Poland
- 2Department of Physiology, Medical University of Bialystok, 15-222 Bialystok, Poland
- 3Regional Centre for Transfusion Medicine, 15-950 Bialystok, Poland
Abstract
Psoriasis is a chronic, immune-mediated inflammatory disease affecting the skin, nails, and joints. Its complex pathogenesis results from interactions between genetic susceptibility and environmental factors and is accompanied by an increased risk of multiple systemic comorbidities, particularly cardiovascular disease. Growing evidence indicates that both conditions share common molecular pathways driven by chronic inflammation, endothelial dysfunction, metabolic disturbances, and immune dysregulation. Among the emerging molecular biomarkers, chemerin, endocan, and growth differentiation factor-15 (GDF-15) have attracted considerable attention due to their role in vascular homeostasis, adipose tissue biology, glucose metabolism, and inflammatory signaling. This review summarizes current evidence on the involvement of these biomarkers in psoriasis and cardiovascular disease, highlighting their contribution to the molecular mechanisms underlying the psoriasis–cardiovascular disease axis. Furthermore, we discussed their potential usefulness as candidate biomarkers for cardiovascular risk. However, prospective validation is strictly required to confirm their clinical utility and establish their incremental predictive value beyond conventional risk factors.
Related
- Food-Derived Substances and Edible Chinese Medicinal Materials in Psoriasis Management: Potential, Evidence, and Perspectives-A Narrative Review.
- Inflammatory biomarkers in pyogenic spinal infection: evidence, limitations, and integrated diagnostic perspectives
- The Association Between Psoriasis and Cardiovascular Comorbidity: A Narrative Review
- Gut microbiota-derived tryptophan metabolites in cardiovascular disease: mechanisms, biomarkers, and precision interventions
- Integrated Single-Cell Transcriptomics, Multi-Omics, and Mendelian Randomization Reveal Ferroptosis-Related Molecular Subtypes and a Genetically Supported Causal Candidate in Psoriasis.
BibTeX
@article{matwiejuk2026molecular,
title = {{Molecular Biomarkers Linking Psoriasis and Cardiovascular Disease: Current Evidence and Clinical Perspectives}},
author = {Mateusz Matwiejuk and Hanna Myśliwiec and Agnieszka Mikłosz and Oksana Jarocewicz and Adrian Chabowski and Iwona Flisiak},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27198918},
url = {https://www.mdpi.com/1422-0067/27/19/8918},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Molecular Biomarkers Linking Psoriasis and Cardiovascular Disease: Current Evidence and Clinical Perspectives
AU - Mateusz Matwiejuk
AU - Hanna Myśliwiec
AU - Agnieszka Mikłosz
AU - Oksana Jarocewicz
AU - Adrian Chabowski
AU - Iwona Flisiak
PY - 2026
DA - 2026/10/08
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27198918
UR - https://www.mdpi.com/1422-0067/27/19/8918
AB - Psoriasis is a chronic, immune-mediated inflammatory disease affecting the skin, nails, and joints. Its complex pathogenesis results from interactions between genetic susceptibility and environmental factors and is accompanied by an increased risk of multiple systemic comorbidities, particularly cardiovascular disease. Growing evidence indicates that both conditions share common molecular pathways driven by chronic inflammation, endothelial dysfunction, metabolic disturbances, and immune dysregulation. Among the emerging molecular biomarkers, chemerin, endocan, and growth differentiation factor-15 (GDF-15) have attracted considerable attention due to their role in vascular homeostasis, adipose tissue biology, glucose metabolism, and inflammatory signaling. This review summarizes current evidence on the involvement of these biomarkers in psoriasis and cardiovascular disease, highlighting their contribution to the molecular mechanisms underlying the psoriasis–cardiovascular disease axis. Furthermore, we discussed their potential usefulness as candidate biomarkers for cardiovascular risk. However, prospective validation is strictly required to confirm their clinical utility and establish their incremental predictive value beyond conventional risk factors.
SN - 1422-0067
ER -